Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Analysts are expressing mixed reactions to Donald Trump's election victory. There are potential positives for the biopharma industry, such as a more friendly FTC for M&A deals. However, concerns have been raised about what role Robert F. Kennedy, Jr. might play in healthcare under Trump's administration. Moving on to recent news, Catalent missed fiscal Q1 revenue...